TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02389426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TCD baseline
Description: Measurement of cerebral circulation parameters with transcranial doppler baseline.~This examination will be performed in patients with multiple sclerosis and in healthy controls.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TCD after bosentan administration
Description: Measurement of cerebral circulation parameters with transcranial doppler after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.~This examination will only be performed in patients with multiple sclerosis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS baseline
Description: Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy baseline.~This examination will be performed in patients with multiple sclerosis and in healthy controls.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS baseline
Description: Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy baseline.~This examination will be performed in patients with multiple sclerosis and in healthy controls.
Study: NCT03495180

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard EEG or SSEP
Description: The gamma frequency range (30 -100 Hz) of standard EEG or somatosensory evoked potential (SSEP) correlate with intensity of an experimental pain stimulus and perceived (self-rating, subjective) pain intensity.
Study: NCT04059185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triple P-Level 2
Description: Triple P-Level 2 (TPL2) consists of a brief, 30 minute, one-on-one consultation with a parenting professional followed by a phone call from that professional roughly 2 weeks later. TPL2 will be delivered on an individual level and consist of a brief, 20 to 40 minute, one-on-one parenting consultation. Parents will receive a positive parenting booklet. They also will be offered parenting tip sheets that are designed to provide basic information on the prevention and management of common behavioral, emotional and developmental problems. All materials are: 1) written in simple English; 2) understandable at a sixth grade reading level; 3) gender-sensitive; and 4) avoid technical and colloquial expression that may pose barriers from non-English speaking backgrounds. Participants will receive a follow-up phone call to check on the family's progress and offer any additional needed advice.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Play Nicely
Description: Play Nicely is a brief, multimedia, computer-based educational program. The online program uses narrated modules to enhance parenting skills and promote effective parental responses to normal aggressive behavior in young children. The parent educational module presents a hypothetical situation of one child harming another. As the module progresses the viewer is given 20 different discipline options from which to choose. Participants are encouraged to click on all the options they wish to learn more about. The different options provide ways to respond to the situation and explain that there are discipline choices that are considered Great options, Good options after others have been tried, or There are better options. The length of the program is dependent on how many of the 20 discipline options the participant chooses to learn about, but generally it can be finished in 20-40 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Our usual care control group participants receive a resource and referral list for local social services
Study: NCT02389426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRS after bosentan administration
Description: Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.~This examination will only be performed in patients with multiple sclerosis.
Study: NCT03968991

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: VISIODOL® (Diagnostic tool)
Description: Tool for assessing pain in the blind subject (with congenital or acquired deficiency)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VISIODOL® (Diagnostic tool)
Description: Tool for assessing pain in the blind subject (with congenital or acquired deficiency)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: VISIODOL® (Diagnostic tool)
Description: Tool for assessing pain in the blind subject (with congenital or acquired deficiency)
Study: NCT03362619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CC-EIEs
Description: 2 to 4 infusions, once a week, for 1x10\^5\~1x10\^7 CTLs/kg via IV, abdominal cavity or intratumoral injection each time
Study: NCT05221398

Intervention type: DRUG
Intervention: Immune Checkpoint Inhibitors Based Adjuvant therapy
Description: Patients in this group will recieve immune checkpoint inhibitors based adjuvant therapy

Intervention type: OTHER
Intervention: Active surveillance
Description: Patients in this group only receive active surveillance
Study: NCT00689104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: Capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Mirabegron
Description: Matching mirabegron placebo tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Mirabegron
Description: Matching mirabegron placebo tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Tolterodine
Description: Matching tolterodine placebo capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Tolterodine
Description: Matching tolterodine placebo capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Tolterodine
Description: Matching tolterodine placebo capsules.
Study: NCT01576237

Intervention type: OTHER
Intervention: blood donation
Description: blood donation with preparative hemapheresis
Study: NCT01819090

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elysee 150 ventilator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elysee 150 ventilator with a ventilation switch control
Study: NCT03369951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline is a semisynthetic derivative of tetracycline and is indicated for the treatment of infections due to susceptible isolates of designated microorganisms.
Study: NCT04004858

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation therapy
Description: Patient will receive 60Gy in 20 fractions as per standard practice

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiation therapy
Description: Patient will receive 60Gy in 20 fractions as per standard practice
Study: NCT03087721

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT-LV
Description: Supervised endurance treadmill training as walking/running uphill, 3 times/week during 12 weeks starting at 85-90% of previously determined maximum oxygen consumption (VO2 max). Warm-up 3 min at 30% of VO2 max, 3 min cool-down. Progression in intensity every 3erd week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CAE
Description: Supervised moderate intensity treadmill training, 3 times/week for 12 weeks starting at 70% of VO2 max. Warm-up 3 min at 30% of VO2 max, 3 min cool-down. Progression in intensity every 3erd week.
Study: NCT00604721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT03622905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DBS-f On
Description: Deep Brain Stimulation of the fornix

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DBS Off
Description: Deep Brain Stimulation of the fornix turned off
Study: NCT05389150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination Pregabalin 150 mg / Tramadol 50 mg
Description: Pregabalin/Tramadol (Laboratorios Silanes S.A. de C.V.), Pharmaceutical Form: Tablet Dosage: 150 mg / 50 mg Administration way: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: From Pfizer S.a. de C.V. Pharmaceutical Form: Capsule Dosage: 150 mg Administration way: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol 50 mg
Description: From Grünenthal de México, S.A. de C.V. Pharmaceutical Form: Capsule Dosage: 50 mg Administration way: oral
Study: NCT03042975

Intervention type: OTHER
Intervention: MRI
Description: Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers

Intervention type: OTHER
Intervention: MRI
Description: Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers

Intervention type: OTHER
Intervention: MRI
Description: Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers

Intervention type: OTHER
Intervention: MRI
Description: Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Blood samples will be collected, the DNA will be extracted and banked for genetic studies.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Blood samples will be collected, the DNA will be extracted and banked for genetic studies.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Blood samples will be collected, the DNA will be extracted and banked for genetic studies.

Intervention type: PROCEDURE
Intervention: Blood draw
Description: Blood samples will be collected, the DNA will be extracted and banked for genetic studies.
Study: NCT04082273

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Femtosecond Laser for Cataract Surgery
Description: Cataract Surgery on study eye according to conventional procedure, with the exception of three steps (Capsulotomy, Lens Fragmentation and Clear Corneal Incisions) which are performed with a Femtosecond Laser in the laser treatment group. Equipment uesd for measurements is the same for both groups and in line with the normal equipment used for the conventional cataract treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Cataract Surgery
Description: Cataract surgery will be performed conventionally, this means the clear corneal incisions will be performed manually by a blade, the capsulorhexis will be performed manually by a hook, and the lens extraction will be done by phacoemulsification
Study: NCT01713829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranberry Beverage
Description: 8 oz cranberry beverage consumed daily for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: 8 oz placebo beverage consumed daily for 12 weeks
Study: NCT02972840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Administered orally (PO)
Study: NCT02242656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opium Tincture USP Deodorized
Description: Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opium Tincture USP Deodorized
Description: Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
Study: NCT00874016

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq
Description: Intubation using Airtraq

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy
Description: Intubation using direct laryngoscopy
Study: NCT02155972

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium infantis
Description: Probiotic supplement
Study: NCT02972840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bendamustine
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Administered intravenously (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT03473249

Intervention type: DRUG
Group type: OTHER
Intervention: Contrast-Enhanced Ultrasound using Lumason
Description: Subjects will undergo a contrast enhanced ultrasound (CEUS) during which a standard greyscale abdominal ultrasound is performed first followed by injection of intravenous contrast with Lumason, and completion of contrast-enhanced ultrasound
Study: NCT02992210

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: 4SCAR-GD2
Study: NCT04041700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osia 2 system
Description: System includes the OSI200 implant surgically placed under the skin behind the ear, the BI300 implant osseointegrated in the bone and the external Osia 2 sound processor.
Study: NCT02208375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vistusertib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vistusertib
Description: Given PO
Study: NCT03552965

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robust Radiotherapy planning
Description: Investigator will plan Intensity-Modulated Radiation Therapy (IMRT) using calculations that minimize the dose of radiation to normal tissue

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Margin-Based Radiotherapy planning
Description: Investigator will plan Intensity-Modulated Radiation Therapy (IMRT) using calculations that introduce a margin to the target area
Study: NCT03571594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5788
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5788
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-5788
Description: Investigational drug
Study: NCT02155972

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT02767687

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noninvasive ventilation
Description: Twenty minutes after extubation all subjects will receive noninvasive ventilation delivered through a facial mask with an ICU ventilator with NIV option for 60 minutes. NIV associates pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O).
Study: NCT01179555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Baseline assessment plus 4 in-home problem solving therapy sessions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Therapy
Description: Baseline assessment plus 4 in-home sessions of supportive therapy.
Study: NCT02167685

Intervention type: DRUG
Intervention: CMX001
Study: NCT03263390

Intervention type: PROCEDURE
Intervention: Bariatric Surgery
Description: Sleeve gastrectomy or Roux-en-Y Gastric Bypass
Study: NCT03464058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 tablets
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 tablets
Description: Oral tablets
Study: NCT03367741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study: NCT03464058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 tablets
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 tablets
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS172767 tablets
Description: Oral tablets
Study: NCT03367741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT03323450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CogMed®
Description: It consists of 25 training sessions which can all be completed online and at home. Each session lasts 30-45 minutes. They must have a computer at home compatible with the CogMed® program.~Brief neuropsychological evaluations will be conducted at 4 time points (these assessments are standard of care):~1. Baseline before the participant is introduced to the CogMed® training program~2. Within 2 weeks of completion of the CogMed® program~3. At 3 months of completion of the CogMed® program to establish maintenance of gains~4. At 6 months of completion of the CogMed® program to establish longer-term maintenance of gains

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CogMed®
Description: It consists of 25 training sessions which can all be completed online and at home. Each session lasts 30-45 minutes. They must have a computer at home compatible with the CogMed® program.~Brief neuropsychological evaluations will be conducted at 4 time points (these assessments are standard of care):~1. Baseline before the participant is introduced to the CogMed® training program~2. Within 2 weeks of completion of the CogMed® program~3. At 3 months of completion of the CogMed® program to establish maintenance of gains~4. At 6 months of completion of the CogMed® program to establish longer-term maintenance of gains
Study: NCT01554111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Picosulfate sodium,
Description: One sachet of picosalax will be given with at least 4 cups of clear fluids.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: phosphosoda rectal enema
Description: The patient will have an enema inserted into the rectum and the liquid contents of the enema will be squeezed into the rectum. The patient will need to hold in the enema for several minutes then can release it.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pico-Salax and Sodium phosphate enema
Description: Pt will take one sachet of Pico-salax the evening prior to procedure and fleet enema 1 hour before leaving home on the morning of the procedure
Study: NCT03414151

Intervention type: OTHER
Intervention: Observation
Description: No intervention administered.

Intervention type: OTHER
Intervention: Observation
Description: No intervention administered.
Study: NCT01647321

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active cycling
Description: The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to actively pedal while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Passive cycling
Description: The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to sit passively on the stationary bile while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
Study: NCT02148744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb7195
Description: Part 1 and 2: Single IV infusion of XmAb7195 or placebo Part 3: Two-dose sequential IV infusion of XmAb7195 or placebo on Day 1 and Day 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00999115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Expanded allogenic adipose-derived adult stem cells
Description: Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure)at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
Study: NCT02024230

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban or Warfarin
Description: a multi-center, prospective, non-randomized, open-label, physician-initiated interventional allocation study either rivaroxaban or warfarin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban or Warfarin
Description: a multi-center, prospective, non-randomized, open-label, physician-initiated interventional allocation study either rivaroxaban or warfarin
Study: NCT04894630

Intervention type: OTHER
Group type: OTHER
Intervention: antimicrobial treatment
Description: Detailed history taking and all clinical findings were collected. Corneal scrapings were obtained from patients and subjected to staining and culture for bacterial and fungal pathogens; Bacterial and fungal growth were identified by standard laboratory procedures.